Anti Infective Agents Market Outlook 2031
The Anti-Infective Agents Market size was USD 144.80 Billion in 2022 and is likely to reach USD 193.94 Billion by 2031, expanding at a CAGR of 3.3% during 2023–2031.
The growth of the market is attributed to the extensive research and development activities for the creation of new drugs which can provide high potency and efficacy towards multi-drug resistant micro-organisms.
Anti-infective agents are medicines whose function is to treat or prevent infections from attacking the host. They have revolutionized the general outlook of healthcare, and are crucial in the treating, curing, & prevention of various infections which were supposedly untreatable. Anti-infective agents are used in the treatment of both minor infections and serious infectious diseases such as tuberculosis and pneumonia.
They can be used for performing routine surgeries and complex procedures including the cesarean sections which can carry the risk of infection. They are also used in providing important immune-suppressive treatments such as chemotherapy for treating people with cancer.
According to the World Health Organization or the WHO, along with the Centers for Disease Control and Prevention or the CDC, one in every 15 hospital patients will be having HIV & Hepatitis C associated infection across the globe and one in four person does not have the vaccination to protect themselves from this disease. The COVID-19 pandemic has hindered the growth of the global anti-infective agents market initially.
However, upon further studies, researchers and scientists found out that the coronavirus has the viral gene of accelerating illness of the hosts. This steered to hospitals, clinics, and healthcare laboratories to focus more on the development of anti-infective agents for the prevention and treatment of diseases and this led to its market growth in the later stages of this pandemic.
Anti Infective Agents Market Market Trends, Drivers, Restraints, and Opportunities
- Increase in spending and investing by the companies towards anti-infective agents is the primary reason for the projection of boosting the market growth during the forecast period, 2023-2031.
- Rapid growth of the biopharmaceutical companies and thereby that industry can become a major factor in the boosting of the global anti-infective agents market during the forecast period.
- High prices for the development of anti-infective agents and high cost of services from the company’s perspective is anticipated to hinder the global anti-infective agents market growth.
- Anti-infective agents when used in high frequencies, especially with no medical inspection can also be harmful for the host including nausea, migraines, and uneasiness in the stomach. This uncertainty can hamper the anti-infective agents market growth.
- R&D investment and technological advancement are expected to offer significant opportunities for the market players. Merck & Co. Inc discovered a new drug called the Zepatier II in October 2020 used for the treatment of genotypes 1 to 4 HCV and is now currently undergoing mass production.
Scope of The Anti Infective Agents Market Report
The report on the global anti-infective agents market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Anti-Infective Agents Market Size - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Types (Antibacterials, Antivirals, and Antifungals), Drugs (Cephalosporins, Penicillin, Fluroquinolones, Macrolides, Carbapenem, Azoles, Echinocandins, Polyenes, and Others), Routes of Administration (Topical, Oral, IV, and Others), and Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, E-Commerce, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast
Key Players Covered in the Report
GlaxoSmithKline plc; Pfizer Inc.; Bayer AG; Sanofi; Merck & Co. Inc.; Bristol-Myers Squibb Company; Abbott; Novartis AG; Johnson & Johnson Services Inc.; Gilead Sciences Inc.; and Astellas Pharma Inc.
Global Anti-Infective Agents Market Segment Insights
Antibacterials segment is projected to represent a large market share
Based on types, the global anti-infective agents market is divided into antibacterials, antivirals, and antifungals. The antibacterials segment is expected to constitute the major share of 49.2 billion in 2019. The major reason attributing to this market growth is the large prescription of antibacterial products along with the broad-spectrum activities of penicillin and cephalosporin.
Meanwhile the antivirals segment is anticipated to grow with a significant CAGR during the forecast period, 2023-2031, owing to the development of new drugs focusing on this segment along with the research and development activities based upon the study of micro-organisms which can be prevented by antivirals.
Azoles segment is estimated to register a huge market share
On the basis of drugs, the global anti-infective agents market is divided into Cephalosporins, Penicillin, Fluroquinolones, Macrolides, Carbapenem, Azoles, Echinocandins, Polyenes, and others. The Azoles segment is expected to constitute the major share of the market in 2019 and is anticipated to grow with a significant CAGR during the forecast period, 2023-2031.
This is attributed to the ability of Azoles to combat with almost any systemic fungal infections present in the host. There has also been further research that shows that these drugs can be used for the vaccination medium for coronavirus.
Oral segment is anticipated to register a huge market share
Based on the routes of administration, the global anti-infective agents market is segmented into topical, oral, IV, and others. The oral segment is expected to constitute the major share of the market in 2019. The major reason attributing to this market growth is the presence of the best pipeline till date along with the new product developments that can be easily administered orally.
Meanwhile the IV segment is anticipated to grow with a significant CAGR during the forecast period, 2023-2031, owing to the rapid delivery of medicines & drugs offered through IV, higher efficacy, and better rate of biological availability.
Hospital pharmacies segment is projected to represent a large market share
Based on distribution channels, the global anti-infective agents market is divided into hospital pharmacies, retail pharmacies, specialty pharmacies, e-commerce, and others. The hospital pharmacies segment is expected to constitute the major share in 2019. The major reason attributing to this market growth is the rising number of hospitalizations in a global scale. The hospitals can provide extensive patient care, insurance policies, treatment, and quick reimbursement through hospital pharmacies.
Meanwhile the e-commerce segment is anticipated to grow with a significant CAGR during the forecast period, 2023-2031, owing to the vast flexibility, convenience, and comfortability when compared to other distribution channels.
North America is anticipated to dominate the market
On the basis of regions, the global anti-infective agents market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to constitute a major share in 2020. This regional market growth can be attributed to the growing research & development expenditure along with the rising in adoption of the latest technology.
The demand of anti-infective agents is increasing rapidly in this region due to the presence of the major market players in the anti-infective agents market, an advantage other regions do not have. The cost of expenditure is significantly lower in North America than that of other economies. However, the market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, 2023-2031, as they have prioritized the cost-efficiency perspective of anti-infective agents combined with their growing population.
The global anti-infective agents market size has been segmented in terms of
Routes of Administration
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- GlaxoSmithKline plc
- Pfizer Inc.
- Bayer AG
- Merck & Co. Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Johnson & Johnson Services Inc.
- Gilead Sciences Inc.
- Astellas Pharma Inc.
Major players competing in the global anti-infective agents market are GlaxoSmithKline plc; Pfizer Inc.; Bayer AG; Sanofi; Merck & Co. Inc.; Bristol-Myers Squibb Company; Abbott; Novartis AG; Johnson & Johnson Services Inc.; Gilead Sciences Inc.; and Astellas Pharma Inc. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
Gilead Sciences Inc. launched two products, namely Sovaldi and Descovy, for the treatment of HCV genotypes for 2 &3 (Sovaldi) and 1 & 4 (Descovy) in 2019 which can be treated in any medium convenient to the patient.